ClinicalTrials.gg
RecruitingNCT07944859IMPACT-PDUpdated Nov 18, 2026

Impact of Advanced Parkinson Therapies on Clinical Status: Deep Brain Stimulation and Foslevodopa/Foscarbidopa

An observational study in Parkinson's Disease (PD) and Malnutrition Elderly, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Medical University of Warsaw · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
92
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 80 studies in Parkinson Disease with a site in Poland — 14 open to participants now, 19 under way, 3 of them phase 3. Parkinson Disease · Poland.

Started
2025
with 4 others
Observational
9 of 80
6 open now
Primary completion
2028-03
later than 10 of 18 live
Registered
78th of 80
by date
Lead sponsor
4 of 80
Medical University of Warsaw

Among the 80 studies in Parkinson Disease with a site in Poland, this one is one of 5 that started in 2025, is one of 9 observational ones, reaches primary completion later than 10 of the 18 other live ones, and was the 78th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

14 of the 80 studies in Parkinson Disease with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Parkinson Disease with a site in Poland, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how treatment with selected advanced therapies for Parkinson's disease affect disease motor symptoms, cognition, body weight, body composition and inflammatory biomarkers in people with advanced Parkinson's disease.

The main questions it aims to answer are:

  • How do clinical symptoms, cognitive function, body composition and blood biomarkers change during the first 12 months after starting the treatment?
  • Are there differences in outcomes between participants treated with DBS and those treated with foslevodopa/foscarbidopa infusion?

Participants will:

  • Undergo deep brain stimulation (DBS) or start continuous subcutaneous foslevodopa/foscarbidopa infusion as part of their routine clinical care.
  • Attend study visits over 12 months and complete assessments of motor and non-motor symptoms, cognition, gait and balance.
  • Provide blood samples and undergo magnetic resonance imaging (MRI) and body composition measurements.
Read the detailed description

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by degeneration of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein. In advanced stages, patients develop motor fluctuations, dyskinesias, and progressive disability despite optimized oral pharmacotherapy, leading to consideration of advanced treatment strategies.

This prospective observational cohort study aims to evaluate clinical, neuropsychological, biochemical, body composition and digital biomarker changes in patients with advanced PD undergoing two advanced therapies: deep brain stimulation (DBS) of the subthalamic nucleus and continuous subcutaneous infusion of foslevodopa/foscarbidopa.

The study will follow participants for 12 months after initiation of advanced therapy. Assessments will be performed at baseline (pre-treatment) and at predefined follow-up visits to evaluate longitudinal changes in motor and non-motor symptoms, cognitive performance, quality of life, gait and balance function, and body composition. Motor outcomes will be assessed using standardized clinical scales including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (UPDRS), with particular emphasis on the motor subsection (Part III). Non-motor symptoms and health-related quality of life will be evaluated using validated questionnaires.

In addition to clinical assessments, the study includes multimodal measures to evaluate potential correlates of disease progression and treatment response. These include peripheral blood tests assessing inflammatory, metabolic, neuroendocrine, and nutritional parameters performed longitudinally during follow-up, as well as multiple assessments of body composition. Neuroimaging with MRI, including tractography, will be performed at baseline for structural characterization of participants. Digital wearable devices will be used intermittently to capture motor fluctuations and dyskinesias.

03

Conditions studied

  • Parkinson's Disease (PD)
  • Malnutrition Elderly

Browse trials for

Keywords

  • Parkinson's disease
  • Deep Brain Stimulation
  • DBS
  • Foslevodopa/foscarbidopa
  • Produodopa
  • Biomarkers
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from patients with advanced Parkinson's disease receiving care at the Department of Neurology, Masovian Bródno Hospital in Warsaw, Poland, a referral center for movement disorders in the region. Recruitment will take place during hospital admissions as part of routine clinical care to assess eligibility for advanced therapies for Parkinson's disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- people with advanced PD, complicated by dyskinesias and fluctuations in motor status, qualified for one of the advanced therapies using the 5-2-1 criteria for PD: surgical treatment with DBS or treatment with subcutaneous infusions of foslevodopa and foscarbidopa.

Exclusion criteria

Exclusion Criteria:

  • previous surgery of the central nervous system
  • concomitant neurological diseases
  • serious circulatory system disease or risk of stroke or heart attack
  • renal or hepatic failure
  • cancer
  • active chronic inflammatory disease
  • to MRI examination (ferromagnetic metal elements in the body, claustrophobia, pregnancy) or measurement of body composition by bioimpedance method (pregnancy, epilepsy, pacemaker, cardioverter-defibrillator)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
92 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Deep Brain Stimulation (DBS)

    Participants with advanced Parkinson's disease treated with bilateral subthalamic deep brain stimulation.

  • Subcutaneous foslevodopa/foscarbidopa infusion

    Participants with advanced Parkinson's disease treated with continuous subcutaneous foslevodopa/foscarbidopa infusion.

06

What researchers measure

Primary outcomes

  1. Change in UPDRS Part III (Motor Examination) score

    Change in motor function assessed using Part III of the MDS-UPDRS. Part III is a clinician-rated motor examination assessing features including bradykinesia, rigidity, tremor, gait, posture, and postural stability. The score ranges from 0 to 132 points, with higher scores indicating greater motor impairment. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change in UPDRS Part I (Non-Motor Aspects of Experiences of Daily Living) score

    Change in non-motor aspects of daily living assessed using Part I of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Part I evaluates non-motor symptoms including cognitive impairment, mood, sleep, pain, urinary symptoms, constipation, fatigue, and other non-motor manifestations. The score ranges from 0 to 52 points , with higher scores indicating greater severity of non-motor symptoms and greater impairment. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months

  2. Change in UPDRS Part II (Motor Aspects of Experiences of Daily Living) score

    Change in motor aspects of daily living assessed using Part II of the MDS-UPDRS. Part II evaluates the impact of motor symptoms on activities of daily living, including speech, eating, dressing, hygiene, handwriting, walking, and mobility. The score ranges from 0 to 52 points, with higher scores indicating greater motor-related disability. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months

  3. Change in UPDRS Part IV (Motor Complications) score

    Change in motor complications assessed using Part IV of the MDS-UPDRS. Part IV evaluates motor fluctuations and dyskinesias associated with Parkinson's disease treatment. The score ranges from 0 to 24 points, with higher scores indicating more severe motor complications. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months

  4. Change in Montreal Cognitive Assessment (MoCA) score

    Change in global cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA assesses several cognitive domains, including visuospatial and executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30 points , with higher scores indicating better cognitive performance. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  5. Change in Parkinson's Disease Questionnaire-39 (PDQ-39) score

    Change in health-related quality of life assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39). The PDQ-39 consists of 39 items across eight domains. The Summary Index is calculated as the mean of the eight domain scores and ranges from 0 to 100, with higher scores indicating poorer health-related quality of life. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  6. Change in Non-Motor Symptoms Scale (NMSS) score

    Change in non-motor symptoms assessed using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 items across nine domains. Each item is scored based on symptom severity (0-3) and frequency (1-4), with the scores multiplied. The total score ranges from 0 to 360, with higher scores indicating more severe non-motor symptoms. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  7. Change in Gastrointestinal Dysfunction Scale for Parkinson's Disease (GIDS-PD) score

    Change in gastrointestinal dysfunction assessed using the Gastrointestinal Dysfunction Scale for Parkinson's Disease (GIDS-PD). The total score ranges from 1 to 108, with higher scores indicating more severe gastrointestinal dysfunction. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  8. Change in Epworth Sleepiness Scale (ESS) score

    Change in daytime sleepiness assessed using the Epworth Sleepiness Scale (ESS). The scale consists of eight items, each scored from 0 to 3. The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  9. Change in Parkinson's Disease Sleep Scale (PDSS) score

    Change in sleep disturbances associated with Parkinson's disease assessed using the Parkinson's Disease Sleep Scale (PDSS). The total score ranges from 0 to 150, with higher scores indicating better sleep quality and fewer sleep disturbances. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  10. Change in Freezing of Gait Questionnaire (FOG-Q) score

    Change in freezing of gait assessed using the Freezing of Gait Questionnaire (FOG-Q). The questionnaire consists of six items, each scored from 0 to 4. The total score ranges from 0 to 24, with higher scores indicating more severe freezing of gait. Unit of Measure: Points on a scale.

    Time frame: Baseline, 3, 6, 9, and 12 months.

  11. Change in Mini-Mental State Examination (MMSE) score

    Change in global cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE assesses orientation, registration, attention and calculation, recall, language, and visuoconstructive abilities. The total score ranges from 0 to 30 points, with higher scores indicating better global cognitive performance. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  12. Change in Executive Clock Drawing Task (CLOX1) score

    Change in executive function assessed using the CLOX1 component of the Executive Clock Drawing Task. CLOX1 requires the participant to draw a clock independently and primarily assesses executive control. The score ranges from 0 to 15 points, with higher scores indicating better performance and lower scores indicating greater impairment. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  13. Change in Executive Clock Drawing Task (CLOX2) score

    Change in visuospatial and visuoconstructive performance assessed using the CLOX2 component of the Executive Clock Drawing Task. CLOX2 requires the participant to copy a clock drawn by the examiner. The score ranges from 0 to 15 points, with higher scores indicating better visuospatial and visuoconstructive performance. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  14. Change in Tower of London (ToL) score

    Change in executive planning and problem-solving performance assessed using the Tower of London (ToL) task. The test assesses planning ability, problem solving, and executive control. The scoring range depends on the specific version and scoring system of the Tower of London used in the study. Higher scores generally indicate better planning performance when the outcome is the number of correctly solved problems, whereas measures such as number of moves, errors, or completion time have the opposite interpretation. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  15. Change in Benton Judgment of Line Orientation (Benton JLO) score

    Change in visuospatial perception assessed using the Benton Judgment of Line Orientation test. The test evaluates the ability to identify and match the angular orientation of lines. For the standard 30-item version, the raw score ranges from 0 to 30 points, with higher scores indicating better visuospatial perception. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  16. Change in Addenbrooke's Cognitive Examination III (ACE-III) score

    Change in global cognitive performance assessed using the Addenbrooke's Cognitive Examination III (ACE-III). The ACE-III assesses five cognitive domains: attention, memory, verbal fluency, language, and visuospatial abilities. The total score ranges from 0 to 100 points, with higher scores indicating better cognitive performance. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  17. Change in Wechsler Adult Intelligence Scale (WAIS) score

    Change in cognitive performance assessed using the Wechsler Adult Intelligence Scale (WAIS). The WAIS assesses multiple domains of cognitive functioning, including verbal comprehension, perceptual reasoning, working memory, and processing speed. Higher standardized scores indicate better cognitive performance. Unit of Measure: Standardized score.

    Time frame: Baseline and 12 months

  18. Change in Rey Auditory Verbal Learning Test (AVLT) score - Total Learning Score

    Change in verbal learning performance assessed using the Rey Auditory Verbal Learning Test (AVLT). A list of 15 words is presented over five learning trials. The total learning score is calculated as the sum of correctly recalled words across Trials I-V and ranges from 0 to 75 words , with higher scores indicating better verbal learning performance. Unit of Measure: Number of correctly recalled words.

    Time frame: Baseline and 12 months

  19. Change in Rey Auditory Verbal Learning Test (AVLT) score - Delayed Recall

    Change in delayed verbal memory assessed using the delayed recall component of the AVLT. After a delay, participants are asked to recall the original 15-word list. The score ranges from 0 to 15 correctly recalled words , with higher scores indicating better delayed verbal memory. Unit of Measure: Number of correctly recalled words.

    Time frame: Baseline and 12 months

  20. Change in Boston Naming Test (BNT) score

    Change in confrontation naming ability assessed using the Boston Naming Test (BNT). In the standard 60-item version, participants are asked to name pictured objects. The total score ranges from 0 to 60 correctly named items, with higher scores indicating better naming and language performance. Unit of Measure: Number of correctly named items.

    Time frame: Baseline and 12 months

  21. Change in Beck Depression Inventory (BDI) score

    Change in severity of depressive symptoms assessed using the Beck Depression Inventory. The total score ranges from 0 to 63 points, with higher scores indicating greater severity of depressive symptoms. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

  22. Change in Beck Anxiety Inventory (BAI) score

    Change in anxiety symptom severity assessed using the Beck Anxiety Inventory (BAI). The questionnaire consists of 21 items evaluating the severity of anxiety symptoms, including physiological, cognitive, and emotional symptoms. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 63 points. Higher scores indicate greater anxiety symptom severity. Unit of Measure: Points on a scale.

    Time frame: Baseline and 12 months

Other outcomes

  1. Change in metabolic, endocrine and nutritional biomarker concentrations

    Change in metabolic and endocrine biomarker concentrations including insulin, leptin, ghrelin, orexin, neuropeptide Y, glucagon-like peptide-1 (GLP-1), growth hormone, insulin-like growth factor-1 (IGF-1), cortisol, lipid profile, total protein, albumin, vitamin B1, vitamin B6, vitamin B12, homocysteine, and methylmalonic acid.

    Time frame: Baseline, 3 and 12 months

  2. Change in inflammatory biomarkers concentrations

    Change in inflammatory and other blood biomarker concentrations assessed through laboratory analysis of peripheral blood samples. The assessment includes cytokines (IL-1β, IL-6, IL-10, IL-18, NF-κB, TGF-β, TNF-α, and RANTES), peripheral blood count parameters, C-reactive protein (CRP), calprotectin, and cystatin C.

    Time frame: Baseline, 3 and 12 months

  3. Change in digital motor biomarkers

    Change in motor fluctuations and medication-induced dyskinesias assessed using electronic wearable devices (BioPoint or Myo).

    Time frame: Baseline, 6 and 12 months

  4. Change in Body Weight

    Change in body weight assessed using a weighing scale. Body weight is measured under standardized conditions, with changes reflecting alterations in overall body mass during the study period. Higher values indicate greater body weight. Unit of Measure: Kilograms (kg).

    Time frame: Baseline, 3 and 12 months

  5. Change in Skinfold Thickness

    Change in subcutaneous fat thickness assessed using skinfold measurements at standardized anatomical sites. Skinfold thickness is measured using skinfold calipers to estimate subcutaneous adipose tissue. Measurements are expressed in millimeters, with higher values indicating greater subcutaneous fat thickness. Unit of Measure: Millimeters (mm).

    Time frame: Baseline, 3 and 12 months

  6. Change in Body Composition Assessed by Bioelectrical Impedance Analysis

    Change in body composition assessed using multi-frequency bioelectrical impedance analysis (BIA) with the Maltron Bioscan 920-II Multi-frequency Analyser. Body composition parameters are evaluated based on the device measurements.

    Time frame: Baseline, 3 and 12 months

  7. Change in Walking Tandem Test score

    Change in dynamic balance and gait coordination assessed using the Walking Tandem Test. The test evaluates the ability to maintain balance and postural stability while walking heel-to-toe along a straight line. Performance is measured by the time required to complete the test, with shorter completion times indicating better dynamic balance, gait coordination, and postural control. Unit of Measure: Seconds (s).

    Time frame: Baseline and 12 months

  8. Change in Tandem Pivot Test score

    Change in dynamic balance and postural control assessed using the Tandem Pivot Test. The test evaluates the ability to maintain balance and postural stability while performing a pivoting movement in a tandem stance position. Performance is assessed based on the ability to complete the movement, with better performance indicating improved dynamic balance, postural control, and coordination. Unit of Measure: Seconds (s).

    Time frame: Baseline and 12 months

  9. Change in Tandem Stance Test (TST) score

    Change in static balance assessed using the Tandem Stance Test (TST). The test evaluates postural stability by measuring the time a participant can maintain a tandem stance, with one foot positioned directly in front of the other. Performance is measured by the duration of maintaining the position, with longer durations indicating better static balance and postural control. Unit of Measure: Seconds (s).

    Time frame: Baseline and 12 months

  10. Change in TUG Manual Test score

    Change in functional mobility and balance during a manual task assessed using the TUG Manual test, performed while carrying a cup. The time required to complete the test is recorded in seconds, with shorter completion times indicating better functional mobility and balance. Unit of Measure: Seconds (s).

    Time frame: Baseline and 12 months

  11. Change in Timed Up and Go (TUG) Test score

    Change in functional mobility and dynamic balance assessed using the Timed Up and Go (TUG) test. The test measures the time required for a participant to stand up from a chair, walk 3 metres, turn around, walk back, and sit down again. The completion time is recorded in seconds, with shorter times indicating better functional mobility and dynamic balance. Unit of Measure: Seconds (s).

    Time frame: Baseline and 12 months

  12. Change in Levodopa Equivalent Daily Dose (LEDD)

    Change in the daily levodopa equivalent dose (LEDD), calculated based on the daily doses of antiparkinsonian medications. Lower values indicate a lower daily dopaminergic medication requirement. Unit of Measure: Milligrams per day (mg/day).

    Time frame: Baseline, 3, 6, 9, and 12 months.

  13. Change in Total Electrical Energy Delivered (TEED)

    Change in total electrical energy delivered by the deep brain stimulation (DBS) system, calculated based on stimulation parameters. The value reflects the amount of electrical energy delivered during stimulation. Unit of Measure: Microwatts (µW).

    Time frame: Baseline, 3, 6, 9, and 12 months.

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology at Mazowiecki Bródnowski Hospital
    Warsaw, Masovian Voivodeship 03-242, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 36 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Nov 18, 2026
StartActual
Mar 19, 2025
Primary completionEst.
Mar 28, 2028
CompletionEst.
Mar 28, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944859
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Mar 19, 2025
Primary completion
Mar 28, 2028 (estimated)
Completion
Mar 28, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Monika Figura, MD, PhD
Contact
neurologia@brodnowski.pl
223265427

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion